Goldman Sachs
TARA icon

Goldman Sachs’s Protara Therapeutics TARA Stock Holding History

Goldman Sachs’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07M Buy
397,981
+334,489
+527% +$1.98M ﹤0.01% 4517
2025
Q4 		$338K Buy
63,492
+49,884
+367% +$277K ﹤0.01% 5805
2025
Q3 		$59.2K Sell
13,608
-123,979
-90% -$401K ﹤0.01% 6151
2025
Q2 		$417K Sell
137,587
-61,667
-31% -$213K ﹤0.01% 5260
2025
Q1 		$849K Sell
199,254
-3,971
-2% -$17.7K ﹤0.01% 4817
2024
Q4 		$1.07M Buy
+203,225
New +$657K ﹤0.01% 4773
2022
Q2 		– Sell
-152,847
Closed -$781K – 6711
2022
Q1 		$781K Sell
152,847
-44,455
-23% -$234K ﹤0.01% 5017
2021
Q4 		$1.33M Buy
197,302
+41,329
+26% +$285K ﹤0.01% 4606
2021
Q3 		$1.08M Buy
155,973
+23,716
+18% +$185K ﹤0.01% 4685
2021
Q2 		$1.29M Buy
+132,257
New +$1.5M ﹤0.01% 4570
2020
Q2 		– Sell
-15,299
Closed -$352K – 5472
2020
Q1 		$352K Buy
+15,299
New +$446K ﹤0.01% 4410

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Goldman Sachs's TARA Position: Q1 2026 in Review

Goldman Sachs increased its Protara Therapeutics (TARA) stake by 527% in Q1 2026, buying an estimated $1.98M and bringing the position to 397,981 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #4517.

Goldman Sachs first reported a position in TARA in Q1 2020 and has held it in 11 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Goldman Sachs held 397,981 shares of Protara Therapeutics worth $2.07M as of Q1 2026.
  • Goldman Sachs bought 334,489 Protara Therapeutics shares in Q1 2026, an estimated $1.98M.
  • Protara Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4517 holding.
  • Goldman Sachs first reported a position in Protara Therapeutics in Q1 2020 and has held it in 11 quarters since.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.